We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Caffeic Acid Phenethyl Ester Ameliorates Pulmonary Fibrosis by Inhibiting Epithelial-Mesenchymal Transition via the Sirt1/PGC-1α/Mitochondrial Axis
Summary
Researchers investigated whether caffeic acid phenethyl ester (CAPE), a natural compound, could inhibit the epithelial-mesenchymal transition (EMT) pathway responsible for pulmonary fibrosis progression. CAPE suppressed EMT markers and fibroblast activation in a mouse model, suggesting it as a candidate therapeutic agent against fibrotic lung disease.
Abstract Pulmonary fibrosis is a severe lung disease characterized by the epithelial-mesenchymal transition (EMT) of alveolar epithelial cells, leading to an increase in fibroblasts or myofibroblasts. Currently, effective therapeutic options for PF remain limited, rendering the inhibition or reversal of EMT a clinically imperative goal. Caffeic acid phenethyl ester (CAPE), a natural flavonoid, exhibits various biological activities, including antioxidant, anti-inflammatory, anticancer, antiviral, and immunomodulatory effects. However, the role of CAPE in EMT-related diseases such as pulmonary fibrosis remains unclear. This study aimed to investigate whether CAPE can target the Sirtuin 1 (Sirt1)/Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) pathway to regulate mitochondrial function, thereby inhibiting EMT and pulmonary fibrosis. Our in vitro and in vivo findings demonstrate that CAPE significantly improves the quantity and function of mitochondria including mitochondrial DNA (mtDNA) content, ATP level, or mitochondrial membrane potential in altered alveolar epithelial cells, increases the ratio of alveolar epithelial to mesenchymal cell markers, and reduces ROS level or collagen expression, ultimately alleviating the degree of fibrosis. These findings establish a robust preclinical foundation for the translational application of CAPE in EMT-related diseases. In conclusion, CAPE may serve as a potential therapeutic agent for pulmonary fibrosis by modulating mitochondrial function through the Sirt1/PGC-1α pathway, underscoring its potential for clinical translation and merit for further investigative efforts in other EMT-associated conditions.
Sign in to start a discussion.
More Papers Like This
Hesperidin inhibits tobacco smoke‑induced pulmonary cell proliferation and EMT in mouse lung tissues via the p38 signaling pathway
Researchers found that hesperidin, a natural flavonoid compound, inhibits tobacco smoke-induced lung cell proliferation and epithelial-mesenchymal transition in mice by suppressing the p38 signaling pathway, suggesting a potential role in reducing lung cancer risk.
Ethanol Extract of Rosa rugosa Ameliorates Acetaminophen-Induced Liver Injury via Upregulating Sirt1 and Subsequent Potentiation of LKB1/AMPK/Nrf2 Cascade in Hepatocytes
Researchers prepared an ethanol extract from Rosa rugosa flower buds and found it significantly reduced liver damage caused by acetaminophen overdose in both cell and mouse models. The extract worked by activating the Sirt1 protein and boosting a protective signaling pathway that counters oxidative stress in liver cells. The study suggests Rosa rugosa extract may have potential as a natural intervention for drug-induced liver injury.
Coal dust nanoparticles induced pulmonary fibrosis by promoting inflammation and epithelial-mesenchymal transition via the NF-κB/NLRP3 pathway driven by IGF1/ROS-mediated AKT/GSK3β signals
Researchers investigated how coal dust nanoparticles trigger lung scarring (pulmonary fibrosis) in coal miners, identifying a molecular chain reaction where nanoparticles activate the IGF1 signaling pathway, generate damaging reactive oxygen species, and ultimately drive inflammation and tissue remodeling. The study pinpoints specific drug targets that could potentially prevent or treat the lung disease that affects millions of miners worldwide.
Senescence in Pulmonary Fibrosis: Between Aging and Exposure
This review examines the role of cellular senescence in pulmonary fibrosis, considering both natural aging processes and environmental exposures such as air pollutants and particulates. It discusses how genomic instability, telomere shortening, and other hallmarks of senescence interact with fibrotic lung disease development in an aging global population.
The interplay of ferroptosis and oxidative stress in pulmonary fibrosis: from mechanisms to treatment
This research review summarizes how a specific type of cell death called ferroptosis may contribute to pulmonary fibrosis, a serious lung disease where scar tissue builds up and makes breathing difficult. Scientists have found that when cells die from iron buildup and damage from harmful molecules, it can worsen lung scarring, but drugs that block this process show promise in animal studies. Understanding this connection could lead to new treatments for people with pulmonary fibrosis, though more research is needed to make sure these potential medicines are safe and effective in humans.